As of 2026-04-08, the EV/EBITDA ratio of Alpine Immune Sciences Inc (ALPN) is -87.88. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ALPN's latest enterprise value is 4,423.93 mil USD. ALPN's TTM EBITDA according to its financial statements is -50.34 mil USD. Dividing these 2 quantities gives us the above ALPN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.3x - 15.1x | 14.2x |
| Forward P/E multiples | 15.6x - 19.7x | 17.8x |
| Fair Price | (10.95) - (10.58) | (11.24) |
| Upside | -116.9% - -116.3% | -117.3% |
| Date | EV/EBITDA |